Editas reni-cel RUBY trial: 18 SCD patients VOE-free; EdiTHAL: 7 TDT patients transfusion-free

Editas Medicine, Inc.

18 SCD patients free of vaso-occlusive events post-reni-cel (follow-up 2.4-22.8 months); mean total Hb >14 g/dL, HbF >40%.
7 TDT patients transfusion-free for 4.1-12.8 months; mean total Hb 12.1 g/dL at month 6, HbF 10.9 g/dL.
No serious adverse events related to reni-cel in either trial; safety profile consistent with myeloablative conditioning.
Median neutrophil engraftment 23 days (SCD and TDT); platelet engraftment 24 days (SCD), 38 days (TDT).
Further clinical update from both trials expected by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.